MFMichael William Flores

Michael William Flores

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael William Flores has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medicaid Value-Based Payment and Quality of Serious Mental Illness Care: Does the Association Vary Across Racial and Ethnic Groups?

    by Gareth Parry, Benjamin Lê Cook, John McConnell, Sharon-Lise T. Normand, Stephanie Renfro, Ana Progovac, Akhil Reddy, Catherine Holmes, Michael William Flores, Marcela Horvitz-Lennon

    While there is growing interest in the implementation of value-based payment (VBP) policies in Medicaid, there is little evidence on whether their impacts among high-need beneficiaries vary by race and ethnicity. We conducted a retrospective cohort study using Oregon Medicaid data and a pre-experimental, treatment-only repeated cross-sectional panel design, to examine whether the association of Oregon’s Medicaid VBP policy with quality varied by race and ethnicity among the state’s beneficiaries with serious mental illness (SMI), that is, those diagnosed with schizophrenia, bipolar disorder, or severe major depressive disorder. We estimated changes in 12 quality measures, by race and ethnicity, pre (2010–2012) and post (2013–2019) VBP implementation. Seven of the 12 measures were designated as VBP performance metrics, with Follow-up after Hospitalization for Mental Illness, 7-day (FUH-7-day), also designated as a bonus-earning incentive metric. The cohort totaled 232,791 person-years (71,599 beneficiaries), with 89% self-described as White and the balance as Latinamerican or Black. The policy was associated with improved quality on FUH-7-day and FUH-30-day, and decreased quality on three physical healthcare measures. The quality impacts varied by race and ethnicity. The policy was associated with the elimination of a pre-existing schizophrenia-only Latinamerican-White FUH-7-day disparity due to the relatively larger Latinamerican post-VBP increase of 18.4 percentage points (95% CI, 2.2–34.6). However, the minority-White disparities in the Antidepressant Medication Management measures persisted post-VBP, and pre-existing advantages for Latinamerican beneficiaries in Cervical Cancer Screening and Avoidance of All-Cause Readmission disappeared because Latinamerican beneficiaries’ performance worsened post-VBP. This study of Oregon’s mature VBP policy contributes first evidence of the potential impacts of Medicaid VBP policies on quality disparities among beneficiaries with SMI. Findings suggest modest gains, potentially related to targeted financial incentives, while also revealing a potential for stagnant or worsening performance.

  • Open Access

    Controlling and monitoring buprenorphine dosing does not benefit treatment engagement and adherence during the post-detoxification period - A pilot randomized controlled trial

    by Zev Schuman-Olivier, Grace Janzow, Michael William Flores, Amanda Sharp, Cassandra Harding, Khary K. Rigg, Holly Hills, Kathleen A. Moore

  • Trends and Disparities in Mental Health Use Among Asian American Sub-groups, 2013–2019

    by Frederick Q. Lu, Michael W. Flores, Nicholas J. Carson, Thomas Le, Benjamin Lê Cook

    Objective The objective of this study was to characterize and compare national estimates of mental healthcare use among White and Asian American groups to provide an update using post Affordable Care Act data. Methods We analyzed yearly cross-sectional data from the 2013–2019 Medical Expenditure Panel Survey, including White (n = 112,590) and Asian American (n = 10,210) individuals, and examined rates of mental healthcare use for Asian (overall), Asian Indian, Chinese, Filipino, and Other Asian individuals relative to White individuals. Using multivariable logistic regression models and predictive margin methods, we estimated overall Asian disparities and Asian subgroup disparities compared to White group rates in mental health care (outpatient, specialty, psychotropic medication) among adults with and without elevated risk for mental illness. Regression models were adjusted for variables related to need for treatment, demographic, and socioeconomic status variables. Results Asian individuals had lower rates of mental healthcare use than White individuals. Unadjusted results and adjusted regression model predictions are consistent in identifying wide disparities in mental health care treatment across risk for mental illness, Asian subgroups, and types of treatment. Conclusions Asian Americans have significantly lower rates of mental healthcare use than White Americans, even among those with elevated risk for mental illness. There is small variation by Asian subgroups but disparities persist across subgroups and types of treatment. Our results imply interventions are needed to improve linguistically, culturally, and ethnically tailored outreach and engagement in treatment services, as well as examining treatment and its effectiveness for Asian American individuals living with psychological distress.


  • Eliciting patient past experiences of healthcare discrimination as a potential pathway to reduce health disparities: A qualitative study of primary care staff

    by Dharma E. Cortés, Ana M. Progovac, Frederick Lu, Esther Lee, Nathaniel M. Tran, Margo A. Moyer, Varshini Odayar, Caryn R. R. Rodgers, Leslie Adams, Valeria Chambers, et al.

    Objective: To understand whether and how primary care providers and staff elicit patients' past experiences of healthcare discrimination when providing care.Data Sources/Study Setting: Twenty qualitative semi‐structured interviews were conducted with healthcare staff in primary care roles to inform future interventions to integrate data about past experiences of healthcare discrimination into clinical care.Study Design: Qualitative study.Data Collection/Extraction Methods: Data were collected via semi‐structured qualitative interviews between December 2018 and January 2019, with health care staff in primary care roles at a hospital‐based clinic within an urban safety‐net health system that serves a patient population with significant racial, ethnic, and linguistic diversity.Principal Findings: Providers did not routinely, or in a structured way, elicit information about past experiences of healthcare discrimination. Some providers believed that information about healthcare discrimination experiences could allow them to be more aware of and responsive to their patients' needs and to establish more trusting relationships. Others did not deem it appropriate or useful to elicit such information and were concerned about challenges in collecting and effectively using such data.Conclusions: While providers see value in eliciting past experiences of discrimination, directly and systematically discussing such experiences with patients during a primary care encounter is challenging for them. Collecting this information in primary care settings will likely require implementation of multilevel systematic data collection strategies. Findings presented here can help identify clinic‐level opportunities to do so.


  • Open Access

    Estimates of Major Depressive Disorder and Treatment Among Adolescents by Race and Ethnicity

    by Michael William Flores, Amanda Sharp, Nicholas J. Carson, Benjamin L. Cook

    Importance: The COVID-19 pandemic has contributed to poorer mental health and a greater need for treatment. Nationally representative estimates of major depressive disorder (MDD) and mental health treatment among US adolescents during the pandemic are needed.Objective: To estimate MDD prevalence among adolescents, evaluate mental health treatment use among adolescents with MDD, and assess differences by race and ethnicity.Design, Setting, and Participants: This cross-sectional analysis of the nationally representative 2021 National Survey on Drug Use and Health included noninstitutionalized US adolescents between the ages of 12 and 17 years (n = 10 743). Analytic weights were applied to all rates and model estimates to be nationally representative and account for sample design and survey nonresponse. Data were collected from January 14 to December 20, 2021, and analyzed from February 11 to April 3, 2023.Exposures: Self-reported race and ethnicity.Main Outcomes and Measures: Dichotomous outcomes of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition), MDD-specific mental health treatment, any type of mental health treatment, telehealth visits, and delays in mental health treatment.Results: The sample included 10 743 adolescents (51.1% male). Self-reported race and ethnicity included 5.1% Asian, 14.1% Black, 23.3% Latinx, 51.2% White, and 6.3% more than 1 race. Ages were evenly distributed: 34.0% aged 12 to 13 years; 33.3% aged 14 to 15 years; and 32.7% aged 16 to 17 years. Adolescents of more than 1 race or ethnicity had the highest MDD rate (26.5%). Compared with White adolescents, the lowest rates of any MDD treatment overall were found among Latinx adolescents (29.2% [95% CI, 22.2%-36.2%]) and those of more than 1 race or ethnicity (21.1% [95% CI, 11.6%-30.7%]). Similar results were found for treatment by any clinician (Latinx, 25.6% [95% CI, 18.8%-32.4%]; >1 race or ethnicity, 19.1% [95% CI, 9.7%-28.6%]), treatment by a mental health specialist (Latinx, 22.9% [95% CI, 16.9%-28.9%]; >1 race or ethnicity, 16.7% [95% CI, 7.1%-26.3%]), treatment by a nonspecialist clinician (Latinx, 7.3% [95% CI, 3.3%-11.3%]; >1 race or ethnicity, 4.8% [95% CI, 1.9%-7.7%]), and use of any psychotropic medication prescription (Latinx, 11.6% [95% CI, 7.3%-15.9%]; >1 race or ethnicity, 8.3% [95% CI, 2.8%-13.7]). Compared with White adolescents, Black adolescents had lower rates of MDD treatment by any clinician (31.7% [95% CI, 23.7%-39.8%]) and by nonspecialist clinicians (8.4% [95% CI, 3.8%-13.2%]) and experienced lower prescription rates for any psychotropic medication (12.6 [95% CI, 4.6%-20.6%]). Asian (16.0% [95% CI, 5.0%-27.2%]) and Latinx (17.8% [95% CI, 12.6%-23.0%]) adolescents had lower rates of virtual mental health treatment compared with White adolescents. Black (19.1% [95% CI, 14.1%-24.2%]) and Latinx (17.9% [95% CI, 15.0%-21.1%]) adolescents had lower rates of appointments transition to telehealth, while Black adolescents (14.1% [95% CI, 10.7%-17.4%]) experienced delays getting their prescriptions.Conclusions and Relevance: During the first full calendar year of the pandemic, approximately 1 in 5 adolescents had MDD, and less than half of adolescents who needed treatment had any mental health treatment. Adolescents in racial and ethnic minority groups, particularly Latinx, experienced the lowest treatment rates. Federal policy should target adolescents as a whole, and minority populations in particular, to ensure equitable treatment access. Efforts should consider the social, racial, ethnic, and cultural determinants of health.


  • Examining Racial/Ethnic Disparities in Tobacco Dependence Treatment Among Medicaid Beneficiaries Using Fifty State Medicaid Claims, 2009–2014

    by Michael William Flores, Brian Mullin, Amanda Sharp, Anika Kumar, Margo Moyer, Benjamin Lê Cook

    In the USA, low-income racial/ethnic minority groups experience higher smoking rates and greater smoking-related disease burden than their White counterparts. Despite the adverse effects, racial/ethnic minorities are less likely to access tobacco dependence treatment (TDT). Medicaid is one of the largest payers of TDT in the USA and covers predominantly low-income populations. The extent of TDT use among beneficiaries from distinct racial/ethnic groups is unknown. The objective is to estimate racial/ethnic differences in TDT use among Medicaid fee-for-service beneficiaries. Using a retrospective study design and 50 state (including the District of Columbia) Medicaid claims (2009–2014), we employed multivariable logistic regression models and predictive margin methods to estimate TDT use rates among adults (18–64) enrolled (≥ 11 months) in Medicaid fee-for-service programs (January 2009–December 2014) by race/ethnicity. The population included White (n = 6,536,004), Black (n = 3,352,983), Latinx (n = 2,264,647), Asian (n = 451,448), and Native American/Alaskan Native (n = 206,472) beneficiaries. Dichotomous outcomes reflected service use in the past year. Any TDT use was operationalized as any smoking cessation medication fill, any smoking cessation counseling visit, or any smoking cessation outpatient visit. In secondary analyses, we disaggregated TDT use into three separate outcomes. Results suggested that Black (10.6%; 95% CI = 9.9–11.4%), Latinx (9.5%; 95% CI = 8.9–10.2%), Asian (3.7%; 95% CI = 3.4–4.1%), and Native American/Alaskan Native (13.7%; 95% CI = 12.7–14.7%) beneficiaries had lower TDT use rates compared to White beneficiaries (20.6%). Similar racial/ethnic treatment disparities were identified across all outcomes. By identifying significant racial/ethnic disparities in TDT use between 2009 and 2014, this study provides a benchmark against which to measure recent interventions in state Medicaid programs improving equity in smoking cessation interventions.


  • Open Access

    Examining Racial/Ethnic Differences in Patterns of Opioid Prescribing: Results from an Urban Safety-Net Healthcare System

    by Michael William Flores, Amanda Sharp, Frederick Lu, Benjamin Lê Cook

    Prescription opioids still account for a large proportion of overdose deaths and contribute to opioid use dependence (OUD). Studies earlier in the epidemic suggest clinicians were less likely to prescribe opioids to racial/ethnic minorities. As OUD-related deaths have increased disproportionately amongst minority populations, it is essential to understand racial/ethnic differences in opioid prescribing patterns to inform culturally sensitive mitigation efforts. The purpose of this study is to estimate racial/ethnic differences in opioid medication use among patients prescribed opioids. Using electronic health records and a retrospective cohort study design, we estimated multivariable hazard models and generalized linear models, assessing racial/ethnic differences in OUD diagnosis, number of opioid prescriptions, receiving only one opioid prescription, and receiving ≥18 opioid prescriptions. Study population (N=22,201) consisted of adult patients (≥18years), with ≥3 primary care visits (ensuring healthcare system linkage), ≥1 opioid prescription, who did not have an OUD diagnoses prior to the first opioid prescription during the 32-month study period. Relative to racial/ethnic minority patients, White patients, in both unadjusted and adjusted analyses, had a greater number of opioid prescriptions filled, a higher proportion received ≥18 opioid prescriptions, and a greater hazard of having an OUD diagnosis subsequent to receiving an opioid prescription (all groups p<0.001). Although opioid prescribing rates have declined nationally, our findings suggest White patients still experience a high volume of opioid prescriptions and greater risk of OUD diagnosis. Racial/ethnic minorities are less likely to receive follow-up pain medications, which may signal low care quality. Identifying provider bias in pain management of racial/ethnic minorities could inform interventions seeking balance between adequate pain treatment and risk of opioid misuse/abuse.


  • Open Access

    US trends in the association of suicide ideation/behaviors with marijuana use among adolescents ages 12–17 and differences by gender and race/ethnicity

    by Michael William Flores, Saul Granados, Benjamin Lê Cook

    Background: In the US over the past decade, there has been a steady increase in marijuana use rates among adolescents, in part due to marijuana legalization laws. It is unknown whether these greater marijuana use rates are associated with rising rates of adolescent suicide ideation and behaviors (plan and attempt) or whether these associations differ by gender or race/ethnicity.Objective: To determine whether marijuana use is associated with suicide ideation/behaviors among adolescents and if differences exist by gender and race/ethnicity.Materials and methods: Using the 2015–2019 National Surveys on Drug Use and Health, we assessed the relationship between marijuana use frequency and suicide ideation/behaviors among adolescents (12–17, n = 73,986). We also examined the association with marijuana use disorder (MUD) and assessed differences by gender and race/ethnicity. Marijuana use frequency in the past year was categorized as no use, non-weekly use, and weekly-plus use. We estimated multivariable logistic regression models, adjusting for sociodemographics, health status, common co-occurring behavioral health disorders, and criminal history. For interpretability, regression coefficients were converted into predicted probabilities using predictive margin methods.Results: In primary analyses, adolescents with non-weekly use and weekly-plus use had higher rates of any suicide ideation, 61.5% (+ 10.4 percentage-points; 95% CI: 7.0–13.8%) and 64.5% (+ 13.4 percentage-points; 95% CI: 9.1–17.7%), relative to no use (51.1%). Non-weekly and weekly-plus use was associated with higher rates of any suicide plan 58.2% (+ 11.8 percentage-points; 95% CI: 7.8–16.0%) and 59.0% (+ 12.6 percentage-points; 95% CI: 6.4–18.9%), and any suicide attempt, 42.0% (+ 11.6 percentage-points; 95% CI: 7.0–16.2%) and 47.3% (+ 16.9 percentage-points; 95% CI: 10.9–22.9%) compared to no use (46.4 and 30.4%, respectively). Similar results were found among adolescents with a MUD (all p < 0.05). Positive associations between marijuana use and suicide ideation/behaviors persisted among males and females as well as White, Black, and Latinx adolescents (all p < 0.05).Conclusion: Between 2015 and 2019, suicide ideation/behaviors increased for adolescents that used marijuana. As marijuana is legalized in more states, public health efforts are needed to curb increases in marijuana use among adolescents and to better understand the causal linkages between marijuana use and suicide ideation/behaviors.


  • Racial and Ethnic Disparities in Childhood ADHD Treatment Access and Utilization: Results From a National Study

    by Kelly Guanhua Yang, Michael William Flores, Nicholas J. Carson, Benjamin Lê Cook

    Objective: The study examined racial-ethnic disparities in access to and utilization of treatment for attention-deficit hyperactivity disorder (ADHD) and other psychiatric diagnoses among children with ADHD. Methods: Nationally representative, cross-sectional data from the Household Component of the Medical Expenditure Panel Survey 2011–2019 were used to examine racial-ethnic disparities in access to and utilization of treatment by children ages 5–17 with ADHD (N=5,838). Logistic regression models were estimated for access outcomes, and generalized linear models were estimated for utilization outcomes. Multivariable regression models adjusted for race-ethnicity, age, sex, and treatment need in accordance with the Institute of Medicine definition of health care disparities. Results: In adjusted analyses, compared with White children with ADHD, Black, Hispanic, and Asian children with ADHD had significantly lower rates of any past-year treatment visit for ADHD or for other psychiatric diagnoses. They also had lower rates of having accessed ADHD medication. Compared with White children, Black and Asian children with ADHD used fewer ADHD medications, and Black and Hispanic children with ADHD had lower overall mental health treatment expenditures. Conclusions: Disparities in ADHD treatment among children from racial-ethnic minority populations may be driven primarily by disparities in access rather than in utilization. Once treatment had been accessed, disparities in utilization were largely accounted for by differences in socioeconomic status. These findings suggest that interventions targeting access to treatment among children from racial-ethnic minority populations may help close existing care gaps.